LBF20207PG49: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=PGH2 was firstly reported as a potent vasoconstrictor.[[Reference:Hamberg_M:Svensson_J:Wakabayashi_T:Samuelsson_B:,Proc. Nat. Acad. Sci. USA,1974,71,345|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Svensson_J:Wakabayashi_T:Samuelsson_B:,Proc. Nat. Acad. Sci. USA,1974,71,345}}]] And PGH2 has been reported as a TP receptor agonist which irreversibly aggregates human platelets at 50-100 ng/ml and also as a suicide substrate for platelet TX synthase proscessing a Ki value of 18 | |Biological Activity=PGH2 was firstly reported as a potent vasoconstrictor.[[Reference:Hamberg_M:Svensson_J:Wakabayashi_T:Samuelsson_B:,Proc. Nat. Acad. Sci. USA,1974,71,345|{{RelationTable/GetFirstAuthor|Reference:Hamberg_M:Svensson_J:Wakabayashi_T:Samuelsson_B:,Proc. Nat. Acad. Sci. USA,1974,71,345}}]] And PGH2 has been reported as a TP receptor agonist which irreversibly aggregates human platelets at 50-100 ng/ml and also as a suicide substrate for platelet TX synthase proscessing a Ki value of 18 mu M .[[Reference:Jones_DA:Fitzpatrick_FA:,J. Biol. Chem.,1990,265,20166|{{RelationTable/GetFirstAuthor|Reference:Jones_DA:Fitzpatrick_FA:,J. Biol. Chem.,1990,265,20166}}]] | ||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Revision as of 14:00, 19 February 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1798 |
| LipidMaps | LMFA03010010 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG49 |
| Prostaglandin H2 | |
|---|---|
| |
| Structural Information | |
| 9α,11α-epidioxy-15S-hydroxy-prosta-5Z,13E-dien-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(CC[C@H](O)C=C[C@@H]([C@H]21)[C@@H](CC=CCCCC(O)=O)[C@@H](OO2)C1)CC |
| Physicochemical Information | |
| PGH2 was firstly reported as a potent vasoconstrictor. Hamberg_M et al. And PGH2 has been reported as a TP receptor agonist which irreversibly aggregates human platelets at 50-100 ng/ml and also as a suicide substrate for platelet TX synthase proscessing a Ki value of 18 mu M . Jones_DA et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
